Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.

ABSTRACT:

Objective

Delayed responses observed with immune checkpoint blockade (ICB) present a challenge for patients with peritoneal malignancies, who risk early symptomatic disease progression requiring treatment discontinuation. While efforts are ongoing to define the biomarkers of response, it is equally important to identify patients at risk for early discontinuation. We sought to investigate the timing of disease progression in epithelial ovarian cancer (EOC) patients treated with ICB and to identify pre-treatment clinical parameters associated with early discontinuation.

Methods

Retrospective analysis was performed on EOC patients treated with ICB at MSKCC from January 2013 to May 2017. Cutoffs for early and very early discontinuation due to disease progression were defined at

SUBMITTER: Boland JL 

PROVIDER: S-EPMC6613945 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature